SCHEMBL10239265

SCHEMBL10239265

COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3OC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.69
KMT2A Q03164 8/20 0.69
THRB P10828 7/20 0.69
BLM P54132 7/20 0.69
RECQL P46063 6/20 0.69
BRCA1 P38398 6/20 0.69
TOP2A P11388 5/20 0.69
TDP1 Q9NUW8 5/20 0.69
HIF1A Q16665 5/20 0.69
SMN1; SMN2 Q16637 5/20 0.69
MAPT P10636 4/20 0.69
MAPK1 P28482 4/20 0.69
PTGS1 P23219 3/20 0.69
CHRM1 P11229 3/20 0.69
TBXA2R P21731 3/20 0.69
KDM4E B2RXH2 3/20 0.69
ALDH1A1 P00352 3/20 0.69
ABCB1 P08183 3/20 0.69
STAT6 P42226 3/20 0.69
HTT P42858 3/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16582272 0.90 MEN1 (0.65) MEN1KMT2ATHRBBLMRECQL
SCHEMBL1755618 0.90 MEN1 (0.65) MEN1KMT2ATHRBBLMRECQL
SCHEMBL2632504 0.90 MEN1 (0.65) MEN1KMT2ATHRBBLMRECQL
SCHEMBL12250542 0.90 MEN1 (0.65) MEN1KMT2ATHRBBLMRECQL
SCHEMBL30408780 0.90 MEN1 (0.65) MEN1KMT2ATHRBBLMRECQL
SCHEMBL15607151 0.90 MEN1 (0.65) MEN1KMT2ATHRBBLMRECQL
SCHEMBL16160572 0.90 MEN1 (0.65) MEN1KMT2ATHRBBLMRECQL
SCHEMBL12000782 0.90 MEN1 (0.65) MEN1KMT2ATHRBBLMRECQL
SCHEMBL12567062 0.89 MEN1 (0.58) MEN1KMT2ATHRBBLMRECQL
SCHEMBL16104166 0.89 S100A4 (0.68) MEN1KMT2ATHRBBLMRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012004005-A1 CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2012-01-12 WO disclosed
US-20100092388-A1 Anthracycline Derivatives NUCLISOME AB (SE) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100092388-A1 Anthracycline Derivatives ABCB1, TOP2A, BRCA1 MEN1 2131/4885KMT2A 1749/4885THRB 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.